Molecular analysis of metastatic CRC in the liver has identified three molecular subtypes that can be coupled with clinical risk scores to inform patient risk.
Bringing together more than 1,000 prostate cancer exomes, researchers uncovered almost 100 significantly mutated genes, including drivers mutated in a fraction of tumors.
With sequence data for hundreds of advanced breast cancer samples, investigators identified genetic alterations shared with — and distinct from — those in primary tumors.
As part of their MI-ONCOSEQ Program, Michigan researchers examined the mutational and transcriptional landscape of 500 metastatic tumors.
Neon Therapeutics is sponsoring a Phase Ib trial of neoantigen-based vaccines in combination with anti-PD-1 treatment in melanoma, lung cancer, and bladder cancer.
New research has identified circulating cell subtypes with ties to better or worse outcomes in individuals with prostate cancer.
In 86 pretreated cancer patients with mismatch repair deficiency, researchers saw objective response rates exceeding 50 percent after anti-PD-1 immunotherapy.
The researchers described gut microbial diversity and composition differences in metastatic melanoma patients who did or did not respond to immunotherapy.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
Analyses of T cell therapy-responsive metastatic HPV-positive cervical cancers suggest the immune cells largely respond to tumor rather than viral antigens.
US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.
A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.
The New York Times writes about the appearance of mosaicism in healthy people.
In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.